How to reach us

Hemanext is based near Boston, MA. Our corporate office is in Lexington, our manufacturing site in Avon.

Corporate Office

Hemanext Inc.
99 Hayden Avenue
Building B, Suite 620
Lexington, MA 02421

Call (781) 301-7474

Manufacturing Plant

Hemanext Inc.
254 Bodwell Street, Suite E
Avon, MA 02322

Call (508) 427-5727
How to Order

United States

Email: info@hemanext.com
Phone: (508) 427-5727

Investigator Initiated Research (IIR)

Hemanext understands the key role that IIRs play in advancing the science of Hemanext ONE® and blood transfusions. Support for these studies will be based on alignment with company-defined areas of strategic interest.

To apply, please fill out the document below and email to medinfo@hemanext.com.

IIR Review Form
Adverse Events (AEs) and Product Complaints

Clinicians and blood establishments should report any complaint alleging a deficiency in Product related to its identity, quality, durability, reliability, safety, effectiveness or performance to Hemanext, Inc. to (508) 427-5727.

General Queries

Please fill out the form below, or send an email to info@hemanext.com.

Medical Information

If you have a medical question or would like to receive literature that is not available on Hemanext.com, please contact our Medical Information Team at medinfo@hemanext.com or call (484) 927-9072. Alternatively, please fill in our Medical Information Request Form.

By producing higher quality RBCs, the Hemanext ONE system has the potential to enable fewer and more effective transfusions for patients. I am truly excited by the possibility of bringing this improved red blood cell replacement therapy to populations in the U.S. that have been waiting for a transformative technology like this one.

Dr. Philip C. Spinella
Professor, Department of Surgery and Department of Critical Care Medicine at University of Pittsburgh

We value our partnership with Hemanext to enhance blood product quality and availability. Hemanext ONE has the potential to strengthen the resiliency of the blood supply, and this FDA authorization is a significant milestone to that end.

Ralph Vassallo, MD, FACP
Executive Vice President, Chief Medical and Scientific Officer of Vitalant

The Hemanext ONE system offers promise to improve the treatment landscape for patients burdened by transfusions and could be an essential step towards performing fewer and better transfusions. Having long championed Hemanext’s transformative initiatives, I eagerly anticipate witnessing the positive influence, right here in the United States, on the advancement of transfusion therapy quality.

Paul M. Ness, MD
Former Director, Division of Transfusion Medicine at Johns Hopkins University and board member of Hemanext

By deoxygenating red cells and maintaining them in their hypoxic state throughout storage, the resulting red cells experience less oxidative stress and oxidative damage, have improved metabolism, and are also more deformable leading to improved micro vascular profusion and less hemolysis.

Dr. Steven Spitalnik, MD
Co-Director of the Laboratory of Transfusion Biology, Colombia University

The preclinical data by Williams et al. show anaerobically stored RBCs achieve multiple clinically important functional resuscitation goals, with a smaller volume of fluid and the FDA benchmark of 24-hour RBC recovery. I look forward to the clinical trials in bleeding patients.

John Holcomb, MD, FACS
University of Alabama at Birmingham

I have had several patients who have received Hemanext hypoxic blood, and several of the patients have personally said thanks for having been given the opportunity and also that they have felt better after transfusion with hypoxic blood compared to conventional transfusion. One must of course be careful not to attach too much importance to such observations, but I would still like to mention that there has been a remarkable tendency towards this.

Håkon Reikvam, MD, PhD
Professor, Department of Clinical Science, University of Bergen, Norway

CONTACT US  |  TERMS OF USE

PRIVACY & COOKIES POLICY

This website may contain information on products or uses of those products that are not authorized in all countries or regions. Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. In Europe Hemanext ONE is CE marked which allows the medical device to be placed in the market in the EEA. Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Hemanext, Hemanext ONE, and the logos are registered trademarks of Hemanext, Inc. © 2026 Hemanext, Inc. All rights reserved.

Contact Us